Biography Flash Emma Raducanu Sidelined by Mystery Illness Eyes Madrid Open Return Amid Evian Glow Up

Emma Raducanu, the British tennis sensation, remains sidelined by lingering post-viral symptoms from a February bug that first hit during the Transylvania Open final, where she crumbled 6-0 6-2 to Sorana Cirstea, according to GB News reports. Her last court sighting was a dismal two-game rout by Amanda Anisimova at Indian Wells nearly a month ago, prompting pullouts from Miami and Linz as she battles chest discomfort and fatigue that just wont budge. Tim Henman noted her uncharacteristic struggles in that defeat, pinning it on fitness woes that demand urgent fixes, per Tennishead. Shes eyeing a cautious return at the Madrid Open on April 21, leveraging her No. 28 ranking for a seeded bye into the second round around April 23 or 24—smart move ahead of clay, with main-draw locks for Italian Open, French Open, and Queens Club grass in June, GB News confirms. Off-court, Raducanu shines in brand spotlight: Shes fronting Evian’s dazzling 200th anniversary global campaign alongside Carlos Alcaraz, Frances Tiafoe, and Céline Boutier, with a buzzworthy portrait featuring artist Jeff Koons, as detailed by Ourscom and Rayon-Boissons. Coaching shakeup: She parted ways with Francisco Roig post-Australian Open flop, a split now echoing as he joins Iga Swiateks team after a brief Giovanni Mpetshi Perricard stint, Le Figaro and Orange Sports report—no fresh drama there, just tennis circles buzzing. No major public appearances or social media splashes in the past few days, and nothing confirmed in the last 24 hours beyond her health watch and Evian glow-up, which could etch lasting biographical gloss amid her injury saga. All verified, no whispers of speculation. Thanks for listening, please subscribe to never miss an update on Emma Raducanu and search the term Biography Flash for more great Biographies. This has been a Quiet Please production. This content was created in partnership and with the help of Artificial Intelligence AI.